News & Events about IP just for you

With 2015 sales of US$1.6Bn and 2017 projected sales of US$2Bn, Bristol-Myers Squibb’s (BMS’) anti-cancer drug dasatinib (Sprycel®) is highly successful and of great interest to competitors. A February 2017 decision from a Technical Board of Appeal at the EPO (European Patent Office) has resulted in the patent covering dasatinib being revoked. But why?

European patent 1169038 [1] covering dasatinib was granted in 2012, opposed in 2013, revoked in January 2016, and the revocation upheld in an appeal deci

The UKIPO have issued a statement that use of omnibus claims will no longer be allowed from 6th April 2017.  Omnibus claims are commonly used in GB applications and are claims that refer generally to the description and/or drawings.

This week, the Supreme Court issued a decision in the Apple vs. Samsung matter which may change the way we effectively register designs in the USA; and specifically, may change the thought process for EU/UK design applicants filing in the USA and vice versa.

What does the new streamlined opposition procedure mean for patent owners? 

The United Kingdom (UK) has voted to leave the European Union (EU) and the process to formally withdraw the UK’s membership of the EU (“Brexit”) will follow. This process is expected to take several years, during which time the UK will remain part of the EU. Nevertheless, as intellectual property (IP) law is one of the areas that is affected by the decision, we wish to take this opportunity to clarify how the decision affects the clients and associates of AIPEX.

After a rigorous process that involved surveys, interviews and extensive research, three of Wynne-Jones IP’s Partners have been listed as ‘IP Stars’ in Managing Intellectual Property’s 2016 World IP Survey. 

The United Kingdom (UK) has voted to leave the European Union (EU) and the process to formally withdraw the UK’s membership of the EU has now started.  This process is expected to take several years, during which time the UK will remain part of the EU.  Nevertheless, as intellectual property (IP) law is one of the areas that is affected by the decision, we wish to take this opportunity to clarify how the decision affects our clients and associates.